Payment overview · 2025
General Payments
$277.87
17 reported records · 8 companies
Healthcare provider profile · identity verified
Keith A Coward, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CLINTON, AR · NPI 1710982871
Verified facts
What the public records show
CMS Open Payments records show Keith A Coward, MD received $277.87 in general payments during 2025 across 17 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 424 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 424 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tresiba by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $112.41 | 40.5% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.76 | 15.0% | 2 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $30.47 | 11.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.49 | 10.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.54 | 6.3% | 1 | 2025 |
| Melinta Therapeutics, LLC | Unresolved — no canonical attribution shown | $16.51 | 5.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.90 | 5.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.79 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $277.87 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $81.29 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.76 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.76 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.12 | 2 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $30.47 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $29.49 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.54 | 1 | 2025 |
Source payment records
|
|||||
| Kimyrsa Normalized: kimyrsa |
Drug | Melinta Therapeutics, LLC | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| Orbactiv Normalized: orbactiv |
Drug | Melinta Therapeutics, LLC | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 424 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 114 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
424 | 67 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
424 | 67 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
114 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 654 | 148 |
| Levothyroxine Sodium | Levothyroxine Sodium | 629 | 128 |
| Lisinopril | Lisinopril | 468 | 125 |
| Atorvastatin Calcium | Atorvastatin Calcium | 434 | 107 |
| Jardiance | Empagliflozin | 424 | 67 |
| Eliquis | Apixaban | 370 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 368 | 71 |
| Omeprazole | Omeprazole | 324 | 68 |
| Metformin Hcl | Metformin Hcl | 319 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 286 | 64 |
| Gabapentin | Gabapentin | 273 | 62 |
| Pioglitazone Hcl | Pioglitazone Hcl | 272 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 261 | 69 |
| Duloxetine Hcl | Duloxetine Hcl | 261 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 257 | 68 |
| Allopurinol | Allopurinol | 252 | 59 |
| Sertraline Hcl | Sertraline Hcl | 239 | 46 |
| Furosemide | Furosemide | 234 | 57 |
| Alprazolam | Alprazolam | 217 | 44 |
| Ezetimibe | Ezetimibe | 191 | 42 |
| Spironolactone | Spironolactone | 185 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 170 | 28 |
| Valsartan | Valsartan | 167 | 31 |
| Pregabalin | Pregabalin | 160 | 33 |
| Trazodone Hcl | Trazodone Hcl | 159 | 39 |
| Lorazepam | Lorazepam | 157 | 32 |
| Torsemide | Torsemide | 153 | 23 |
| Meloxicam | Meloxicam | 149 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 140 | 23 |
| Montelukast Sodium | Montelukast Sodium | 139 | 37 |
| Carvedilol | Carvedilol | 133 | 28 |
| Chlorthalidone | Chlorthalidone | 133 | 25 |
| Atenolol | Atenolol | 131 | 31 |
| Donepezil Hcl | Donepezil Hcl | 126 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 122 | 23 |
| Entresto | Sacubitril/Valsartan | 121 | 13 |
| Losartan Potassium | Losartan Potassium | 116 | 29 |
| Simvastatin | Simvastatin | 116 | 21 |
| Ozempic | Semaglutide | 114 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 31 |
| Tramadol Hcl | Tramadol Hcl | 106 | 23 |
| Famotidine | Famotidine | 105 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 33 |
| Memantine Hcl | Memantine Hcl | 92 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 29 |
| Metformin Hcl Er | Metformin Hcl | 91 | 21 |
| Prednisone | Prednisone | 90 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 90 | 17 |
| Xarelto | Rivaroxaban | 86 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 21 |
| Aripiprazole | Aripiprazole | 73 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 66 | 16 |
| Buspirone Hcl | Buspirone Hcl | 64 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 63 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 16 |
| Fentanyl | Fentanyl | 58 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 12 |
| Divalproex Sodium | Divalproex Sodium | 57 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 16 |
| Fenofibrate | Fenofibrate | 56 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 56 | 19 |
| Levetiracetam | Levetiracetam | 55 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 55 | 12 |
| Methylprednisolone | Methylprednisolone | 54 | 40 |
| Warfarin Sodium | Warfarin Sodium | 53 | suppressed |
| Potassium Chloride | Potassium Chloride | 51 | 19 |
| Clonidine Hcl | Clonidine Hcl | 50 | 11 |
| Propranolol Hcl | Propranolol Hcl | 50 | suppressed |
| Azithromycin | Azithromycin | 49 | 45 |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | 11 |
| Mirtazapine | Mirtazapine | 48 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | suppressed |
| Latanoprost | Latanoprost | 47 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 45 | suppressed |
| Finasteride | Finasteride | 45 | suppressed |
| Colchicine | Colchicine | 44 | 11 |
| Baclofen | Baclofen | 43 | suppressed |
| Brilinta | Ticagrelor | 43 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 43 | 17 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 43 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 43 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | 13 |
| Cephalexin | Cephalexin | 41 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 12 |
| Estradiol | Estradiol | 41 | suppressed |
| Risperidone | Risperidone | 40 | suppressed |
| Ibuprofen | Ibuprofen | 39 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 37 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Vascepa | Icosapent Ethyl | 35 | suppressed |
| Linzess | Linaclotide | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Lovastatin | Lovastatin | 31 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 29 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 29 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 27 | 16 |
| Albuterol Sulfate | Albuterol Sulfate | 26 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Clonidine | Clonidine | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 23 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 17 |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Mupirocin | Mupirocin | 19 | 13 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Exemestane | Exemestane | 18 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 18 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Gemtesa | Vibegron | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Tresiba | Insulin Degludec | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | 11 |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $277.87 · 17 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPVAXIVE, EVENITY, GARDASIL 9, JARDIANCE, Jornay PM, Kimyrsa, MOUNJARO, Orbactiv, Ozempic, Rybelsus, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error